Example: air traffic controller
HIGHLIGHTS OF PRESCRIBING INFORMATION
Hepatocellular Carcinoma (HCC) • For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). (1.3) Endometrial Carcinoma (EC) • In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is not microsatellite
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
HIGHLIGHTS OF PRESCRIBING INFORMATION - …
www.lenvima.comFULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 1.1 Differentiated Thyroid Cancer 1.2 Renal Cell Carcinoma 1.3 Hepatocellular Carcinoma
Clinical information guide - lenvima.com
www.lenvima.comPatients with locally recurrent or metastatic RAI-refractory DTC (N=392) All patients must have had radiographic evidence of disease progression within 12 months prior
OR Eisai Assistance Program 1-866-61-EISAI …
www.lenvima.comIf signed by legal representative, describe the nature of his/her relationship with the patient: Name of Patient Name of Legal Representative Signature
Related documents
HIGHLIGHTS OF PRESCRIBING INFORMATION Gastric Cancer ...
packageinserts.bms.com• Hepatocellular carcinoma • 1 mg/kg followed by ipilimumab 3 mg/kg on the same day every 3 weeks for • Adjuvant treatment of resected esophageal or gastroesophageal cancer 240 mg every 2 weeks or 480 mg every 4 weeks for 16 weeks, then 480 mg every 4 weeks for total treatment duration of 1 year. (2.2) • Esophageal squamous cell carcinoma
Nek2 augments sorafenib resistance by regulating the ...
jeccr.biomedcentral.comlocalization of β-catenin in hepatocellular carcinoma Ling Deng1, Jingyuan Sun1, Xiaohui Chen1, Li Liu2* and Dehua Wu1* Abstract Background: Sorafenib is the first-line treatment for advanced-stage hepatocellular carcinoma (HCC). Several studies have shown that the up-regulation of β-catenin plays a role in sorafenib resistance in HCC ...
YERVOY U.S. Prescribing Information
packageinserts.bms.comHepatocellular Carcinoma • Treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib, in combination with nivolumab. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon ...
AASLD Guidelines for the Treatment of Hepatocellular …
www.aasld.orgtreatment of hepatocellular carcinoma (HCC) occur-ring in the setting of adults with cirrhosis. Unlike pre-vious AASLD practice guidelines, the current guideline was developed in compliance with the Insti-tute of Medicine standards for trustworthy practice guidelines and uses the Grading of Recommendation Assessment, Development and Evaluation ...
Modified RECIST (mRECIST) Assessment for Hepatocellular ...
imaging.cancer.govMeasurement of response rate in hepatocellular carcinoma (HCC) has become a con-troversialissue.TheWorld Health Organization (WHO)criteria underestimate the actual response rate; thus, they were amended in 2000 by a panel of experts convened by the European Association for the Study of the Liver (EASL) to take into account treatment-